AMT-260

With FDA filing for key gene therapy pushed back 6 months, uniQure opens the pocketbook to refresh the pipeline
Endpoints
Tue, 06/22/21 - 10:37 pm
uniQure
M&A
Corlieve Therapeutics
AMT-260
gene therapy
temporal lobe epilepsy